<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03152708</url>
  </required_header>
  <id_info>
    <org_study_id>CAN-B1-008-L-009</org_study_id>
    <nct_id>NCT03152708</nct_id>
  </id_info>
  <brief_title>CAN008 Biomarker CD95 Ligand and CpG2 Methylation in Chinese Patients With Glioblastoma</brief_title>
  <official_title>The Exploratory Study on CAN008 Biomarker CD95 Ligand and Its Promoter (CpG2) Methylation in Chinese Patients With Glioblastoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CANbridge Life Sciences Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CANbridge Life Sciences Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study was conducted on the post-operative tumor tissues from 62 GBM patients. 20 slices
      are necessary for all the CD95 and CpG2 test in the central lab by the methods of
      immunisation and DNA methylation.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 1, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2017</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>CD95 Ligand Positive Rate</measure>
    <time_frame>0 day</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>CpG2 Positive Rate</measure>
    <time_frame>0 day</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">62</enrollment>
  <condition>Glioblastoma</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Chinese GBM patients
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Chinese nationality

          -  No limits on Gender and age

          -  First diagnosed GBM

          -  Brain tumor tissue cytological diagnosis of glioblastoma (GBM, pleomorphic
             glioblastoma, WHO level IV)

        Exclusion Criteria:

          -  Other types of glioma by histological diagnosis

          -  Tumor tissue not eligible for the central laboratory testing standard

          -  No enough tumor tissue for the central laboratory test
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jinsong Wu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Huashan Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jack Hou</last_name>
    <phone>00862152996609</phone>
    <email>jhou@canbridgepharma.com</email>
  </overall_contact>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 11, 2017</study_first_submitted>
  <study_first_submitted_qc>May 11, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 15, 2017</study_first_posted>
  <last_update_submitted>September 20, 2017</last_update_submitted>
  <last_update_submitted_qc>September 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

